Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

New England Journal of Medicine

Volumn 334, Issue 22, 1996, Pages 1435-1439

  Taha, Ali S ^a,e   Hudson, Nicholas ^b   Hawkey, Christopher J ^b   Swannell, Anthony J ^b   Trye, Penelope N ^c   Cottrell, Jeremy ^c   Mann, Stephen G ^c   Simon, Thomas J ^d   Sturrock, Roger D ^a   Russell, Robin I ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c Merck Sharp & Dohme Limited   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DUODENUM ULCER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DUODENAL ULCER; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; RISK FACTORS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 9344236529     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199605303342204     Document Type: Article

References (22)

1. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926-32.
2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ 1990;300:278-84. [Erratum, BMJ 1990;300:764.]
3. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
4. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993;32:990-5.
5. Graham DY, White RH, Morelarid LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
6. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
7. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992;327:1575-80.
8. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
9. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
10. Daneshmend TK, Prichard PJ, Bhaskar NK, Millns PJ, Hawkey CJ. Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology 1989;97:944-9.
11. Aabakken L, Bjornbeth BA, Weberg R, Viksmoen L, Larsen S, Osnes M. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Aliment Pharmacol Ther 1990;4: 295-303.
12. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
14. Skander MP, Ryan FP. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ 1988;297:833-4.
15. French PC, Darekar BS, Mills JG, Wood JR. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroenterol Hepatol 1994;6:1141-7.
16. Simon TJ, Berger ML, Hoover ME, Stauffer LA, Berlin RG. A dose-ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDs): results of a U.S. multicenter trial. Am J Gastroenterol 1994;89:A1644. abstract.
17. Rowe PH, Starlinger MJ, Kasdon E, Hollands MJ, Silen W. Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. Gastroenterology 1987;93:863-71.
18. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990;31:514-7.
19. Rohner HG, Gugler R. Treatment of active duodenal ulcers with famotidine: a double-blind comparison with ranitidine. Am J Med 1986;81(4B):13-6.
20. Savarino V, Mela GS, Scalabrini P, Di Timoteo E, Magnolia MR, Celle G. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. Digestion 1987;37:103-9.
21. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990;259:G462-G467.
22. Hudson N, Taha AS, Sturrock RD, Russell RI, Hawkey CJ. The influence of Helicobacter pylori colonisation on gastroduodenal ulceration in patients on non-steroidal anti-inflammatory drugs. Gut 1992;33:Suppl:S42. abstract.